



ABN 82 010 975 612

Level 18, 101 Collins Street
Melbourne, Victoria 3000 Australia
Telephone: + 61 7 3088 7926
Facsimile: + 61 7 3394 4394

Results of 2016 Annual General Meeting

Melbourne, Australia, 25 November 2016. TBG Diagnostics Limited (ASX: TDL, OTC: TDLAF) (the **Company** or **TBG**) today releases the results of the 2016 Annual General Meeting.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, the Company advises that the resolutions detailed in the Notice of Meeting were determined as follows:

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Directors' Remuneration Report	Ordinary	7,719,828 87.54%	244,846 2.77%	854,696 9.69%	13,857	Carried on a show of hands			Carried
2 Election of Director - Mr Chang Chia-Chuan (Edward Chang)	Ordinary	149,757,027 99.41%	32,073 0.02%	854,696 0.57%	112,405	Carried on a show of hands			Carried
3 Re-election of Director – Mr Chen Yu-Zen (Eugene Cheng)	Ordinary	149,862,638 99.42%	30,462 0.02%	854,696 0.56%	8,405	Carried on a show of hands			Carried
4 Approval of Additional Share Issue capacity Under Listing Rule 7.1A	Special	149,664,578 99.35%	123,478 0.08%	854,696 0.57%	113,449	Carried on a show of hands			Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.



ABN 82 010 975 612

Level 18, 101 Collins Street
Melbourne, Victoria 3000 Australia
Telephone: + 61 7 3088 7926
Facsimile: + 61 7 3394 4394

For more information:

Blair Lucas
Company Secretary
+61 7 3088 7926
+61 403 358 638

About TBG Diagnostics

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020 (This is huge to say we operate in the IVD market. More realistically, we operate in the MDx market which is growing from 10% (\$6Bn USD) to 25.2% (\$25Bn USD) of total IVD market share by 2024.)

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases